ArticlePediatric obesity2026
Liver Fat Is Associated With Elevated FGF21 in Youth With Obesity but Without MASLD.
Article in Pediatric obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver Fat Is Associated With Elevated FGF21 in Youth With Obesity but Without MASLD.Pediatric obesity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundYouth with obesity are at risk for accumulating liver fat, even below the threshold for metabolic dysfunction-associated steatotic liver disease (MASLD), defined as ≥ 5% by MRI. While prior studies suggest that sub-threshold liver fat may carry metabolic risk, the role of fibroblast growth factor-21 (FGF21)-a liver-derived hormone responsive to metabolic stress-has not been well characterised in this context.
objectivesTo examine the association between liver fat < 5% and metabolic markers in pubertal youth with obesity, with a focus on FGF21.
methodsThis secondary cross-sectional analysis included 58 pubertal adolescents with obesity (62% female; mean age 14.7 ± 1.7 years) and liver fat < 5% by MRI-proton density fat fraction (PDFF). Fasting glucose, insulin, lipids, leptin, adiponectin and FGF21 were measured. Insulin sensitivity was estimated by homeostatic model assessment of insulin resistance (HOMA-IR). Associations between PDFF and metabolic markers were analysed using Spearman correlations and multivariable regression, adjusted for age, sex, race, ethnicity and body mass index standard deviation score (BMI SDS).
resultsThe median PDFF was 2.68%. PDFF correlated positively with BMI SDS, waist circumference, glucose, triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) and FGF21. In adjusted models, PDFF remained independently associated with FGF21 (Beta = 52 pg/mL per 1% increase; p = 0.02), even after log transformation. No associations were observed with HOMA-IR, leptin, or adiponectin.
conclusionsAmong pubertal youth with obesity and liver fat below the MASLD threshold, modest increases in PDFF were independently associated with higher FGF21. These findings support the potential utility of FGF21 as a biomarker of early hepatic-metabolic stress in the framework of 'pre-MASLD' state-similar to pre-diabetes before the development of overt steatosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.